We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+55.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.22B
AUM Growth
+$309M
Cap. Flow
+$82.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
72.94%
Holding
57
New
4
Increased
7
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$148M
2
GERN icon
Geron
GERN
+$14.8M
3
TRML
Tourmaline Bio
TRML
+$11.8M
4
ENGN icon
enGene Therapeutics
ENGN
+$6.01M
5
PHVS icon
Pharvaris
PHVS
+$5.77M

Top Sells

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$38.2M
2
ACLX
Arcellx
ACLX
+$18.1M
3
VTYX
Ventyx Biosciences
VTYX
+$14.7M
4
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$13M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$7.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
26
Sera Prognostics
SERA
$75.6M
$9.87M 0.81%
1,650,440
-205,571
-11% -$597K
SVRA icon
27
Savara
SVRA
$1.11B
$9.82M 0.8%
2,088,323
+174,974
+9% +$671K
SLN
28
Silence Therapeutics
SLN
$528M
$8.86M 0.73%
+510,204
New +$5.73M
ALLK
29
DELISTED
Allakos
ALLK
$8.16M 0.67%
2,988,000
– –
PHVS icon
30
Pharvaris
PHVS
$2.37B
$7.99M 0.65%
+285,000
New +$5.77M
ORIC icon
31
Oric Pharmaceuticals
ORIC
$1.39B
$7.82M 0.64%
849,681
+71,737
+9% +$519K
RYZB
32
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$6.87M 0.56%
110,581
-522,995
-83% -$13M
ENGN icon
33
enGene Therapeutics
ENGN
$120M
$6.26M 0.51%
+678,705
New +$6.01M
CMPX icon
34
Compass Therapeutics
CMPX
$357M
$5.55M 0.45%
3,556,023
– –
IOVA icon
35
Iovance Biotherapeutics
IOVA
$1.95B
$5.33M 0.44%
655,057
– –
TIL icon
36
Instil Bio
TIL
$49.2M
$4.76M 0.39%
624,340
+1
+0% +$7
ARWR icon
37
Arrowhead Research
ARWR
$12.6B
$4.2M 0.34%
137,411
– –
BOLT icon
38
Bolt Biotherapeutics
BOLT
$7.59M
$3.94M 0.32%
176,065
-17,500
-9% -$341K
DCTH icon
39
Delcath Systems
DCTH
$454M
$3.56M 0.29%
855,191
-1,000,000
-54% -$3.28M
RZLT icon
40
Rezolute
RZLT
$479M
$3.22M 0.26%
3,242,842
+2,758,403
+569% +$2.53M
UNCY icon
41
Unicycive Therapeutics
UNCY
$142M
$3.01M 0.25%
347,015
– –
DBVT
42
DBV Technologies
DBVT
$811M
$2.58M 0.21%
270,888
– –
ALGS icon
43
Aligos Therapeutics
ALGS
$29.4M
$2.36M 0.19%
141,881
– –
CDXS icon
44
Codexis
CDXS
$154M
$1.18M 0.1%
388,144
– –
WHWK
45
Whitehawk Therapeutics
WHWK
$205M
$1.03M 0.08%
509,572
– –
QTTB icon
46
Q32 Bio
QTTB
$480M
$225K 0.02%
20,559
– –
DTIL icon
47
Precision BioSciences
DTIL
$188M
$51.2K ﹤0.01%
4,675
– –
ACLX
48
DELISTED
Arcellx
ACLX
– –
-503,565
Closed -$18.1M
ACRS icon
49
Aclaris Therapeutics
ACRS
$835M
– –
-898,631
Closed -$6.16M
BCAB icon
50
BioAtla
BCAB
$5.56M
– –
-10,684
Closed -$908K
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Vivo Capital held 57 positions worth $1.22B, up 34% from $913M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Vivo Capital deployed $82.5M of net new capital in Q4 2023, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Tourmaline Bio: 591,882 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Consumer Staples and Materials.

On the sell side, the largest reduction was RayzeBio, Inc. Common Stock, an estimated $13M trimmed.

  • Vivo Capital's largest Q4 2023 buy was Tourmaline Bio: 591,882 shares worth $15.5M.
  • Vivo Capital added most to Soleno Therapeutics in Q4 2023, an estimated $148M increase.
  • Vivo Capital's biggest Q4 2023 reduction was RayzeBio, Inc. Common Stock, cutting an estimated $13M.
  • Vivo Capital fully exited Sinovac Biotech, Ltd in Q4 2023, selling an estimated $38.2M.
  • Vivo Capital's ten largest holdings make up 73% of its $1.22B portfolio in Q4 2023.
  • Vivo Capital opened 4 new positions and closed 10 in Q4 2023.
  • Vivo Capital's portfolio value rose 34% quarter-over-quarter to $1.22B.

Based on Vivo Capital's 13F filing for Q4 2023, filed 7 Feb 2024.